Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$22.95 USD
+0.61 (2.73%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $22.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
APLS 22.95 +0.61(2.73%)
Will APLS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLS
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say
Repligen (RGEN) Lags Q2 Earnings Estimates
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
Other News for APLS
Apellis price target raised by $4 at JPMorgan, here's why
Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call Presentation
Apellis (APLS) Price Target Raised as Market Stabilizes
RBC Capital Raises Price Target for Apellis Pharmaceuticals (APLS) | APLS Stock News